Multiprocessor scheduling of periodic tasks in a hard real-time environment

The problem of preemptive scheduling a set of periodic tasks on multiprocessors is studied from the point of view of meeting their service requirements before their respective deadlines. Sufficient conditions which permit full utilization of the multiprocessor using the given scheduling algorithms are derived. The complexity of the scheduling algorithms in terms of the number of scheduled tasks and the number of processors and upper bounds on the number of preemptions in a given time interval and for any single task are also derived. We also give a schema for modifying existing schedules at little run-time cost when tasks arrive or leave the system on-line

An optimal multiprocessor real-time scheduling algorithm

An optimal scheduling algorithm is described that feasibly schedules a set ofmperiodic tasks onnprocessors before their respective deadlines, if the task set satisfies certain conditions. The complexity of this scheduling algorithm in terms of the number of scheduled tasks and the number of processors and upper bounds on the number of preemptions in a given time interval and for any single task is also derived. The optimal algorithm is shown to be particularly useful when schedules are built from the integral flow values obtained from the corresponding maximum flow network

Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.

Key PointsQuestionCan poloxamer 188, an agent that is reported to reduce blood viscosity and cell-cell interactions, effectively reduce the duration of vaso-occlusive episodes (painful crises) in hospitalized patients with sickle cell disease? FindingsIn this randomized clinical trial that included 388 children and adults with sickle cell disease, treatment with poloxamer 188 vs placebo resulted in mean time to last dose of parenteral opioids during vaso-occlusive episodes of 81.8 vs 77.8 hours, a difference that was not statistically significant. MeaningAmong patients with sickle cell disease, poloxamer 188 did not significantly shorten the duration of painful vaso-occlusive episodes

Effect of poloxamer 188 vs placebo on painful vaso-occlusive episodes in children and adults with sickle cell disease : a randomized clinical trial

Key PointsQuestionCan poloxamer 188, an agent that is reported to reduce blood viscosity and cell-cell interactions, effectively reduce the duration of vaso-occlusive episodes (painful crises) in hospitalized patients with sickle cell disease? FindingsIn this randomized clinical trial that included 388 children and adults with sickle cell disease, treatment with poloxamer 188 vs placebo resulted in mean time to last dose of parenteral opioids during vaso-occlusive episodes of 81.8 vs 77.8 hours, a difference that was not statistically significant. MeaningAmong patients with sickle cell disease, poloxamer 188 did not significantly shorten the duration of painful vaso-occlusive episodes